HER3 Assay Portfolio Service
With the aid of our advanced platform and extensive experience in tumor marker assay discovery, Creative Biolabs is dedicated to developing one-stop HER3 assay portfolio services, which will help our customers meet their research needs.
Tumor Target HER3
HER3 is a member of the human epidermal growth factor receptor (HER) family which includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. HER family members share a common molecular structure consisting of an extracellular domain (ECD), a transmembrane domain, an intracellular domain with tyrosine kinase (TK) activity, and a c-terminal tail. As a special member of the HER family, HER3 has little or no intrinsic tyrosine kinase activity, while it usually forms heterodimers with other receptor tyrosine kinases (RTKs) to activate oncogenic signaling in cancer cells.
HER3 overexpression is relevant to several tumor types including breast, ovarian, prostate, gastric, lung, melanoma, colorectal, and squamous cell carcinoma. In melanoma and pancreatic carcinoma, HER3 is the preferred heterodimeric partner for EGFR. For HER2-mediated breast cancer, HER3 serves as a vital co-receptor of HER2, which expression is essential for cell survival and proliferation. What is more, several studies discovered that compensatory upregulation of HER3 accompanied by the persistent PI-3K/Akt signaling is associated with resistance to EGFR-targeted therapy.
HER3-targeted Therapies
During the last decades, several anti-HER3 therapies have exhibited anti-tumor activity in vivo and showed promise as novel cancer therapeutics. The targeted therapies against HER3 include the applications of mono-/bi-specific antibodies, CAR-T therapy, vaccines, HER3-locked nucleic acid-based RNA inhibitors, and small molecule inhibitors. The main mechanisms are as follows:
i) trapping or blocking ligand binding sites;
ii) abrogating dimerization of HER3 with other EGFR family members;
iii) triggering the internalization of the HER3 receptor to exert toxic effects for tumor cells;
iv) recruiting immune cells to kill cancer cells expressing endogenous HER3.
Fig.1 HER3 targeted therapies in preclinical and clinical trials. (Mishra, 2018)
Custom HER3 Assay Portfolio Service
Taking advantage of advanced technology platforms and deep scientific and regulatory understanding in immune-oncology, Creative Biolabs has developed a novel one-stop service covering HER3 assay portfolio for our global clients to discover and identify tumor target molecules’ potential and develop the targeted therapies.
Features of Our Service
HER3 assay portfolio services are MOA-reflective and suitable for many types of sample leads.
Highly reproducible assays for potency for therapeutic drug discovery and development.
From initial design and optimization all the way down to preclinical study with well-recorded data and organized reports.
If there is any query, please contact us for more details.
Reference
-
Mishra, R.; et al. HER3 signaling and targeted therapy in cancer. Oncology reviews. 2018, 12(1): 355.
For Research Use Only | Not For Clinical Use
Download our brochure